Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCyte InternationalTPE:4178 -2.39%7 Quick Ratio is 9.15 as of Mar. 2026, which is 2% above its 10-year median of 8.98. GuruFocus rates TPE:4178 with a GF Score™ of 7/100. The stock has 4 warning signs investors should review. Among 1,407 Biotechnology companies, StemCyte International ranks better than 75.48% on this metric.
StemCyte International (TPE:4178) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
StemCyte International Quick Ratio Related Terms
StemCyte International Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4178 vs VRTX, REGN, RVMD: Quick Ratio Comparison
For the Biotechnology subindustry, StemCyte International's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCyte International Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCyte International's Quick Ratio distribution charts can be found below:
* The bar in red indicates where StemCyte International's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
StemCyte International's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StemCyte International (TPE:4178) has a Quick Ratio of 9.15 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on StemCyte International and its competitors. This is near median its historical median of 8.98. Over the past decade, StemCyte International's Quick Ratio has ranged from 2.75 to 9.41. According to the industry distribution chart, StemCyte International ranks #345 out of 1407 companies in the Biotechnology industry, placing it in the top 24.5%.
Is StemCyte International's Quick Ratio too high?
StemCyte International's current Quick Ratio of 9.15 is near median its 10-year median of 8.98. Over the past 10 years, this metric has ranged from a low of 2.75 to a high of 9.41. The Biotechnology industry median Quick Ratio is 3.50. StemCyte International's value of 9.15 is 161.4% above this industry median. Based on the distribution chart, StemCyte International ranks #345 out of 1407 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, StemCyte International has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does StemCyte International's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCyte International ranks #345 out of 1407 companies for Quick Ratio. This places StemCyte International in the top 25% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.50. StemCyte International's value of 9.15 is 161.4% above this benchmark. Historically, StemCyte International's own Quick Ratio has ranged from 2.75 to 9.41 over the past decade. While the company's 10-year median is 8.98 vs. the industry median of 3.50, StemCyte International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.50, based on 1,407 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. StemCyte International's current Quick Ratio of 9.15 is 161.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on StemCyte International and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCyte International's current Quick Ratio is 9.15, which is near median its own 10-year median of 8.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCyte International stock overvalued right now?
StemCyte International (TPE:4178) has a current Quick Ratio of 9.15. The current Quick Ratio is 9.15, which is near median its 10-year median of 8.98 and 161.4% above the Biotechnology industry median of 3.50. StemCyte International's overall GF Score™ is 7/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For StemCyte International (TPE:4178), the current Quick Ratio is 9.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
StemCyte International Ltd is engaged in developing new stem cell drugs and test, process, and store umbilical cord blood (UCB)-related cells. The company's main operating activities are providing umbilical cord blood collection, processing and storage services. Its reportable segments are the United States, Taiwan, and Others. The majority of revenue is derived from the United States.
7GF Score
Get the complete analysis for TPE:4178
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4178 has been successfully added to your 
